A prospective comparative study between trabeculectomy with MMC versus trabeculectomy with Ologen for patients with open angle glaucoma one year follows up. Introduction: Recent studies reported that the use of a biodegradable collagen glycosamino-glycan matrix (ologen) implant in the subconjunctival space offers a method for wound healing modulation beside MMC after glaucoma surgery. Ologen is composed of a three dimensional disc-shaped porous structure that implanted over scleral flap before closure of conjunctiva during trabeculectomy. Ologen regulate aqueous flow by keeping pressure on top of the scleral flap and by acting as a reservoir, as aqueous gets absorbed into its porous structure. Patient and Methods: A prospective randomized clinical study was done in military eye hospital. Fifty eyes were presented by POAG or PEX glaucoma included in this study. 25 eyes treated by trabeculectomy wit MMC (MMC group) and the other 25 eyes treated by trabeculectomy with implant of ologen (ologen group). Follow up for one year was done. Results: It is found that; mean IOP in ologen group was 13.16±1.68mmHg and in the MMC group mean IOP 16.47±3.56mmHg. Regarding to postoperative antiglaucoma medications, in ologen group, the mean was 0.31±0.48 compared to MMC group 1.06±0.85 drugs, p-value is 0.05. Success rate was 21/25 eyes (84%) in the ologen group, in comparison to MMC group, success rate was 19/25 eyes (76%). Conclusion: This new degradable collagen implant (ologen) improves and normalizes filtering surgical wound healing with more loosely organized bleb tissue and healthy than blebs augmented with MMC